ArticleOncoTargets and therapy2018
Twenty-gene-based prognostic model predicts lung adenocarcinoma survival.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Expression and potential molecular mechanisms of miR‑204‑5p in breast cancer, based on bioinformatics and a meta‑analysis of 2,306 cases.Molecular medicine reports · 2019Pooled it
- Hierarchical Multi-Label Classification With Gene-Environment Interactions in Disease Modeling.Statistics in medicine · 2025Article
- Review
- Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma.Journal of translational medicine · 2023Observational
- Identification of potential tumor antigens and immune subtypes for lung adenocarcinoma.Medical oncology (Northwood, London, England) · 2023Article
- Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.Oncology research · 2023Article
- Article
- A Novel Predictive Model Incorporating Ferroptosis-Related Gene Signatures for Overall Survival in Patients with Lung Adenocarcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- A prognostic model of non small cell lung cancer based on TCGA and ImmPort databases.Scientific reports · 2022Article
- Identification and Validation of 7-lncRNA Signature of Epigenetic Disorders by Comprehensive Epigenetic Analysis.Disease markers · 2022Article
- Identification of LINC00665-miR-let-7b-CCNA2 competing endogenous RNA network associated with prognosis of lung adenocarcinoma.Scientific reports · 2021Article
- Article
- A Robust Panel Based on Mitochondrial Localized Proteins for Prognostic Prediction of Lung Adenocarcinoma.Oxidative medicine and cellular longevity · 2021Article
- A gene-based survival score for lung adenocarcinoma by multiple transcriptional datasets analysis.BMC cancer · 2020Article
- Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.BMC bioinformatics · 2020Article
- Novel prognostic molecular markers in lung cancer.Oncology letters · 2020Review
- Single-center versus multi-center data sets for molecular prognostic modeling: a simulation study.Radiation oncology (London, England) · 2020Article
- IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis.Journal of translational medicine · 2020Article
- Six-gene-based prognostic model predicts overall survival in patients with uveal melanoma.Cancer biomarkers : section A of Disease markers · 2020Article
- A model of twenty-three metabolic-related genes predicting overall survival for lung adenocarcinoma.PeerJ · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLung adenocarcinoma (LAC) accounts for more than a half of non-small cell lung cancer with high morbidity and mortality. Progression of treatment has not accelerated the improvement of its prognosis. Hence, it is an urgent need to develop novel biomarkers for its early diagnosis and treatment. MATERIALS AND
methodsIn this study, we proposed to identify LAC survival-related genes through comprehensive analysis of large-scale gene expression profiles. LAC gene expression data sets were obtained from The Cancer Genome Atlas (TCGA). Identification of differentially expressed genes (DEGs) in LAC compared with adjacent normal lung tissues was first performed followed by univariate Cox regression analysis to obtain genes that are significantly associated with LAC survival (SurGenes). Then, we conducted sure independence screening (SIS) for SurGenes to identify more reliable genes and the prognostic signature for LAC survival prediction. Another two lung cancer data sets from TCGA and Gene Expression Omnibus (GEO) were used for the validation of prognostic signature.
resultsA total of 20 genes were obtained, which were significantly associated with the overall survival (OS) of LAC patients. The prognostic signature, a weighted linear combination of the 20 genes, could successfully separate LAC samples with high OS from those with low OS and had robust predictive performance for survival (training set: DISCUSSION: The prognostic signature combined with multi-gene expression profiles provides a moderate OS prediction for LAC and should be helpful for appropriate treatment method selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.